A New York team and Rgenix have found that LXR agonists can treat metastatic melanoma. The findings open up new therapeutic real estate for LXR agonists that pharma companies discontinued in cardiovascular disease.
TARGETS & MECHANISMS
The inability of heart cells to divide rapidly enough to repair damage is a major impediment to regenerating heart tissue after myocardial infarction. A U.S. team has used cyclin A2 gene therapy to induce cardiomyocyte division and improve heart function in pig models of MI.
Loss-of-function mutations in chromatin-modifying proteins remain largely intractable. Separate teams, including a group from Novartis, have identified synthetic lethal interactions that could be exploited to help treat cancers with mutations in the SWI/SNF chromatin-remodeling complex.
A U.S. team has leveraged the cardioprotective activity of TIMP3 using a formulation and delivery strategy that avoids off-target effects. Preclinical data indicate that the procedure could help prevent heart failure after myocardial infarction, but identifying the right patients could be a challenge.
Inhibiting integrin alpha9 to treat autoimmune disease; overexpressing STS in the liver to improve metabolism and alleviate obesity; using HIV gp120 immunogens to generate prophylactic vaccines; and more...
MARS-Seq for analyzing transcriptional states in thousands of single cells; iPS cell-derived immortalized megakaryocyte progenitor cells as a renewable source for human platelets; micrococcal nuclease-activated fluorescent oligonucleotide probes to image Staphylococcus infection; and more...